MX2021002382A - Sales y formas cristalinas de modulador alosterico positivo gabaa. - Google Patents

Sales y formas cristalinas de modulador alosterico positivo gabaa.

Info

Publication number
MX2021002382A
MX2021002382A MX2021002382A MX2021002382A MX2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A MX 2021002382 A MX2021002382 A MX 2021002382A
Authority
MX
Mexico
Prior art keywords
salts
crystal forms
positive allosteric
allosteric modulator
gabaa positive
Prior art date
Application number
MX2021002382A
Other languages
English (en)
Inventor
Nelson B Olivier
Kiran Reddy
Gabriel Martinez Botella
Magnus Ronn
Paul A Laskar
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2021002382A publication Critical patent/MX2021002382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se relaciona con sales del Compuesto 1, con sus formas cristalinas, con métodos para su preparación, con composiciones farmacéuticas que las comprenden y con métodos para su uso.
MX2021002382A 2018-08-31 2019-08-30 Sales y formas cristalinas de modulador alosterico positivo gabaa. MX2021002382A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725805P 2018-08-31 2018-08-31
US16/517,369 US10562930B1 (en) 2018-08-31 2019-07-19 Salts and crystal forms of GABAA positive allosteric modulator
PCT/US2019/049103 WO2020047434A1 (en) 2018-08-31 2019-08-30 Salts and crystal forms of gabaa positive allosteric modulator

Publications (1)

Publication Number Publication Date
MX2021002382A true MX2021002382A (es) 2021-08-11

Family

ID=69528249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002382A MX2021002382A (es) 2018-08-31 2019-08-30 Sales y formas cristalinas de modulador alosterico positivo gabaa.

Country Status (13)

Country Link
US (4) US10562930B1 (es)
EP (1) EP3710465B1 (es)
JP (2) JP7199739B2 (es)
KR (1) KR20210054546A (es)
CN (1) CN113473991A (es)
AU (1) AU2019333310A1 (es)
BR (1) BR112021003727A2 (es)
CA (1) CA3111193A1 (es)
IL (1) IL281143A (es)
MA (1) MA50921A (es)
MX (1) MX2021002382A (es)
TW (2) TWI823999B (es)
WO (1) WO2020047434A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007902B1 (pt) * 2014-10-16 2023-12-05 Sage Therapeutics, Inc Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN113939298A (zh) * 2018-12-14 2022-01-14 普拉西斯精密医药公司 用于治疗抑郁症的方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
EP4294819A1 (en) 2021-02-18 2023-12-27 Praxis Precision Medicines, Inc. Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
US20240207366A1 (en) 2021-04-27 2024-06-27 Kyungpook National University Industry-Academic Cooperation Foundation Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023164386A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634039T2 (de) 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
CA2372342A1 (en) 1999-04-29 2000-11-09 Derk J. Hogenkamp 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
PL2168585T3 (pl) 2005-06-09 2012-05-31 Euro Celtique Sa Kompozycje farmaceutyczne steroidów neuroaktywnych i ich zastosowania
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
BR112017007902B1 (pt) * 2014-10-16 2023-12-05 Sage Therapeutics, Inc Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central
AU2018364659A1 (en) 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN113939298A (zh) 2018-12-14 2022-01-14 普拉西斯精密医药公司 用于治疗抑郁症的方法

Also Published As

Publication number Publication date
KR20210054546A (ko) 2021-05-13
TW202024108A (zh) 2020-07-01
US10927141B2 (en) 2021-02-23
BR112021003727A2 (pt) 2021-05-25
MA50921A (fr) 2020-09-23
EP3710465A1 (en) 2020-09-23
TW202408461A (zh) 2024-03-01
AU2019333310A1 (en) 2021-04-08
CA3111193A1 (en) 2020-03-05
US20200071350A1 (en) 2020-03-05
US20220024967A1 (en) 2022-01-27
IL281143A (en) 2021-04-29
TWI823999B (zh) 2023-12-01
CN113473991A (zh) 2021-10-01
US10562930B1 (en) 2020-02-18
EP3710465A4 (en) 2020-09-23
EP3710465B1 (en) 2024-08-14
TWI850138B (zh) 2024-07-21
WO2020047434A1 (en) 2020-03-05
JP7199739B2 (ja) 2023-01-06
JP2021504297A (ja) 2021-02-15
JP2023036708A (ja) 2023-03-14
US20240140985A1 (en) 2024-05-02
US20200255471A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2019015744A (es) Composiciones farmaceuticas.
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
PH12018500777A1 (en) Farnesoid x receptor modulators
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017003421A2 (pt) formas sólidas cristalinas de 6-carbóxi-2-(3,5-diclorofenil)-benzoxazol
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
MY197698A (en) Oxysterols and methods of use thereof
MX2017014035A (es) Formas solidas novedosas.
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
PH12020550133A1 (en) Crystal forms of immunomodulators
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
EP4327880A3 (en) Solid state form of ribociclib succinate
CL2017003475A1 (es) Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
JOP20200030A1 (ar) مركب خماسي الحلقة
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1